A staging system for hepatocellular carcinoma

prognostic factors in Ugandan patients

A. Primack, Charles Vogel, S. K. Kyalwazi, J. L. Ziegler, R. Simon, P. P. Anthony

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

A staging scheme for hepatocellular carcinoma was presented at an International Symposium on Liver Cancer in Kampala, Uganda in 1971. Historical, clinical, and laboratory aspects of that staging scheme were examined for prognostic significance in 72 untreated patients with this disease studied at the Uganda Cancer Institute. The median survival for the entire group was 1 mth. The presence of a serum bilirubin concentration of greater than 2 mg/100 ml or weight loss greater than 25% of body weight were the poorest prognostic features. Other factors with prognostic significance were visible abdominal collateral circulation, ascites, tumor differentiation, and serum levels of alkaline phosphatase, SGOT, alpha fetoprotein, and proline hydroxylase. A modified staging scheme is presented which defines three prognostically different groups of Ugandan patients. It is hoped this staging scheme will serve as a stimulus for analysis of similar prognostic features in other populations of patients with hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)1357-1364
Number of pages8
JournalCancer
Volume35
Issue number5
DOIs
StatePublished - Dec 1 1975
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Uganda
Prolyl Hydroxylases
Collateral Circulation
alpha-Fetoproteins
Liver Neoplasms
Aspartate Aminotransferases
Serum
Bilirubin
Ascites
Alkaline Phosphatase
Weight Loss
Neoplasms
Body Weight
Survival
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A staging system for hepatocellular carcinoma : prognostic factors in Ugandan patients. / Primack, A.; Vogel, Charles; Kyalwazi, S. K.; Ziegler, J. L.; Simon, R.; Anthony, P. P.

In: Cancer, Vol. 35, No. 5, 01.12.1975, p. 1357-1364.

Research output: Contribution to journalArticle

Primack, A. ; Vogel, Charles ; Kyalwazi, S. K. ; Ziegler, J. L. ; Simon, R. ; Anthony, P. P. / A staging system for hepatocellular carcinoma : prognostic factors in Ugandan patients. In: Cancer. 1975 ; Vol. 35, No. 5. pp. 1357-1364.
@article{b538dc6fcf87434092729afc9cc7b50a,
title = "A staging system for hepatocellular carcinoma: prognostic factors in Ugandan patients",
abstract = "A staging scheme for hepatocellular carcinoma was presented at an International Symposium on Liver Cancer in Kampala, Uganda in 1971. Historical, clinical, and laboratory aspects of that staging scheme were examined for prognostic significance in 72 untreated patients with this disease studied at the Uganda Cancer Institute. The median survival for the entire group was 1 mth. The presence of a serum bilirubin concentration of greater than 2 mg/100 ml or weight loss greater than 25{\%} of body weight were the poorest prognostic features. Other factors with prognostic significance were visible abdominal collateral circulation, ascites, tumor differentiation, and serum levels of alkaline phosphatase, SGOT, alpha fetoprotein, and proline hydroxylase. A modified staging scheme is presented which defines three prognostically different groups of Ugandan patients. It is hoped this staging scheme will serve as a stimulus for analysis of similar prognostic features in other populations of patients with hepatocellular carcinoma.",
author = "A. Primack and Charles Vogel and Kyalwazi, {S. K.} and Ziegler, {J. L.} and R. Simon and Anthony, {P. P.}",
year = "1975",
month = "12",
day = "1",
doi = "10.1002/1097-0142(197505)35:5<1357::AID-CNCR2820350518>3.0.CO;2-8",
language = "English",
volume = "35",
pages = "1357--1364",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - A staging system for hepatocellular carcinoma

T2 - prognostic factors in Ugandan patients

AU - Primack, A.

AU - Vogel, Charles

AU - Kyalwazi, S. K.

AU - Ziegler, J. L.

AU - Simon, R.

AU - Anthony, P. P.

PY - 1975/12/1

Y1 - 1975/12/1

N2 - A staging scheme for hepatocellular carcinoma was presented at an International Symposium on Liver Cancer in Kampala, Uganda in 1971. Historical, clinical, and laboratory aspects of that staging scheme were examined for prognostic significance in 72 untreated patients with this disease studied at the Uganda Cancer Institute. The median survival for the entire group was 1 mth. The presence of a serum bilirubin concentration of greater than 2 mg/100 ml or weight loss greater than 25% of body weight were the poorest prognostic features. Other factors with prognostic significance were visible abdominal collateral circulation, ascites, tumor differentiation, and serum levels of alkaline phosphatase, SGOT, alpha fetoprotein, and proline hydroxylase. A modified staging scheme is presented which defines three prognostically different groups of Ugandan patients. It is hoped this staging scheme will serve as a stimulus for analysis of similar prognostic features in other populations of patients with hepatocellular carcinoma.

AB - A staging scheme for hepatocellular carcinoma was presented at an International Symposium on Liver Cancer in Kampala, Uganda in 1971. Historical, clinical, and laboratory aspects of that staging scheme were examined for prognostic significance in 72 untreated patients with this disease studied at the Uganda Cancer Institute. The median survival for the entire group was 1 mth. The presence of a serum bilirubin concentration of greater than 2 mg/100 ml or weight loss greater than 25% of body weight were the poorest prognostic features. Other factors with prognostic significance were visible abdominal collateral circulation, ascites, tumor differentiation, and serum levels of alkaline phosphatase, SGOT, alpha fetoprotein, and proline hydroxylase. A modified staging scheme is presented which defines three prognostically different groups of Ugandan patients. It is hoped this staging scheme will serve as a stimulus for analysis of similar prognostic features in other populations of patients with hepatocellular carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0016833599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016833599&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197505)35:5<1357::AID-CNCR2820350518>3.0.CO;2-8

DO - 10.1002/1097-0142(197505)35:5<1357::AID-CNCR2820350518>3.0.CO;2-8

M3 - Article

VL - 35

SP - 1357

EP - 1364

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -